📰 Primary Endpoint News
Page 2 - Primary Endpoint News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Primary Endpoint. Real-time updates on events, politics, business and more.
November 12, 2023
Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high risk for cardiovascular events INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) ...
November 2, 2023
Kodiak Sciences Inc. announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology to be held November 3-6, 2023 in San Francisco....
October 16, 2023
NB: this is a summary translation of the press release original drafted in Japanese for the disclosure required in compliance...
September 26, 2023
Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company focused on rare diseases, announced Tuesday positive top-line results from the randomized withdrawal period of Study C602 of DCCR (Diazoxide Choline) for Prader-Willi syndrome or PWS.
September 25, 2023
T ianeptine - tianeptine 1 Stablon. Summary of product characteristics. Les Laboratoires Servier Industrie ; 2014. 2 PubChem. Accessed November 10, 2022....
September 25, 2023
Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.
August 15, 2023
Invivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Call Transcript August 12, 2023 Operator: Welcome to the Invivyd Second Quarter 2023 Business and Financial Results Update Call. I will now turn the call over to Gabriella Linville-Engler, Director of External Communications. Gabriella Linville-Engler: Thank you for joining us today. Before we get started, I want to tend […]
August 12, 2023
UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call Transcript August 10, 2023 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-1.03, expectations were $-1.13. Operator: Good morning, ladies and gentlemen. Thank you for standing by. And welcome to the UroGen Pharma’s Second Quarter 2023 Earnings Call. Please be advised that today’s conference is being […]
June 29, 2023
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securit...